A new inhaled treatment shows promise in helping patients recover faster from severe respiratory infections by targeting lung inflammation.
Severe infections such as influenza, COVID-19, and pneumonia can trigger an overactive immune response, leading to lasting lung damage. This new therapy focuses on Angiopoietin-like protein 4 (ANGPTL4), a molecule that exacerbates vascular permeability and lung tissue damage.
Delivered directly into the lungs like asthma medication, this localised approach concentrates the drug at the injury site, minimizing systemic side effects. Preclinical models demonstrated reduced inflammation, fluid build-up, and scarring in lungs affected by bacterial pneumonia and influenza.
Early safety studies suggest the therapy remains localized within the lungs, supporting a favorable safety profile. The research is progressing towards advanced preclinical testing and preparation for human clinical trials.